• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bristol-Myers Squibb (NY: BMY )

    54.43 +1.53 (+2.89%)
    Streaming Delayed Price Updated: 11:50 AM EDT, Oct 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 8,191,853
    Open 52.83
    Bid (Size) 54.42 (4)
    Ask (Size) 54.44 (6)
    Prev. Close 52.90
    Today's Range 52.41 - 54.53
    52wk Range 39.35 - 58.06
    Shares Outstanding 2,222,113,553
    Dividend Yield 4.19%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    This Is What Whales Are Betting On Bristol-Myers Squibb
    Via Benzinga
    IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
    IGM Biosciences shifts focus to autoimmune diseases, reduces oncology research, and appoints former Bristol Myers Squibb executive as CEO. The company aims to extend its cash runway into 2027. 
    Via Benzinga

    Performance

    YTD
    +3.17%
    +3.17%
    1 Month
    +7.74%
    +7.74%
    3 Month
    +34.56%
    +34.56%
    6 Month
    +3.20%
    +3.20%
    1 Year
    -5.91%
    -5.91%

    More News

    Read More
    Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
    Via The Motley Fool
    Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
    Via Benzinga
    Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
    From Prime Medicine, Inc.
    Via GlobeNewswire
    NYSE:BMY Shows Potential for a Breakout.
    Via Chartmill
    What Analysts Are Saying About Bristol-Myers Squibb Stock
    Via Benzinga
    3 Surprisingly Underrated Stocks to Buy Right Now
    Via The Motley Fool
    U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
    From Bristol Myers Squibb
    Via Business Wire
    Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
    Via Benzinga
    Exposures Product Safety
    Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
    From Bristol Myers Squibb
    Via Business Wire
    14 Stocks Gain Momentum As August Inflation Comes In Below Expectations
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
    Via Benzinga
    Exposures Product Safety
    Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Wall Street On Wait-And-Watch Mode Ahead Of Inflation Data, Bitcoin Holds Above 65.5K: Analyst Says Volatility Ahead Providing Better Entry Point Into Long-term Bull Market
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
    Via Investor's Business Daily
    Exposures Product Safety
    FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
    Via Benzinga
    Exposures Product Safety
    Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
    Via Benzinga
    Exposures Product Safety
    Analysts Think There's Still Time to Get in on Edgewise, Up 332%
    Via MarketBeat
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
    Via Benzinga
    Exposures Product Safety
    Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
    Via Investor's Business Daily
    2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
    Via Investor's Business Daily
    Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
    Via Benzinga
    New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
    From Bristol Myers Squibb
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.